Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease: The TELEX Randomized Clinical Trial.

ABSTRACT:

Importance

Patients with lower extremity peripheral artery disease (PAD) have reduced lower extremity perfusion, impaired lower extremity skeletal muscle function, and poor walking performance. Telmisartan (an angiotensin receptor blocker) has properties that reverse these abnormalities.

Objective

To determine whether telmisartan improves 6-minute walk distance, compared with placebo, in patients with lower extremity PAD at 6-month follow-up.

Design, setting, and participants

Double-blind, randomized clinical trial conducted at 2 US sites and involving 114 participants. Enrollment occurred between December 28, 2015, and November 9, 2021. Final follow-up occurred on May 6, 2022.

Interventions

The trial randomized patients using a 2 × 2 factorial design to compar

SUBMITTER: McDermott MM 

PROVIDER: S-EPMC9533188 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature